The global health economics and outcomes research market share was valued at USD 1.50 Billion in 2024, driven by the rising number of mergers and acquisitions amongst leading companies across the globe. The market is anticipated to grow at a CAGR of 13.50% during the forecast period of 2025-2034 to achieve a value of USD 5.32 Billion by 2034. This impressive growth highlights the increasing importance of HEOR in shaping healthcare policies, improving patient outcomes, and supporting evidence-based decision-making for both public and private healthcare systems.
Understanding the Health Economics and Outcomes Research (HEOR) Market
Health economics and outcomes research is a specialized field that evaluates the economic impact, clinical effectiveness, and overall value of healthcare interventions. HEOR combines quantitative research, statistical modeling, and real-world evidence to assess how medical treatments, drugs, and healthcare services perform in actual patient populations compared to controlled clinical settings.
In an era where healthcare costs are rising and payers demand value-based solutions, HEOR plays a crucial role in guiding reimbursement decisions, informing health technology assessments (HTA), and supporting regulatory approvals. Pharmaceutical companies, medical device manufacturers, healthcare providers, and government bodies increasingly rely on HEOR to demonstrate the clinical and economic benefits of their products and services.
Key Market Drivers
Several factors are contributing to the rapid expansion of the HEOR market:
1. Growing Emphasis on Value-Based Healthcare
Global healthcare systems are shifting from volume-based to value-based care models, focusing on patient outcomes rather than the number of procedures performed. HEOR supports this transition by providing robust data on the cost-effectiveness of treatments, enabling better decision-making for payers and providers.
2. Increasing Pharmaceutical R&D Investment
The pharmaceutical industry is investing heavily in research and development, with a growing need to justify the pricing of innovative drugs. HEOR helps companies demonstrate therapeutic and economic value, which is essential for gaining market access and favorable reimbursement status.
3. Rise in Mergers and Acquisitions
As noted in the market valuation, the increasing number of mergers and acquisitions among major HEOR service providers and pharmaceutical companies is driving market growth. Consolidation enables better integration of clinical, economic, and real-world evidence capabilities, allowing companies to offer comprehensive solutions to clients.
4. Expansion of Real-World Evidence (RWE) Usage
Regulators and payers are placing greater importance on real-world evidence, which provides insights into treatment effectiveness in everyday practice. HEOR teams are leveraging RWE to support policy development, improve treatment guidelines, and ensure cost-effective healthcare delivery.
Market Segmentation Analysis
The HEOR market can be segmented based on service type, therapeutic area, and end-user.
By Service Type:
- Economic Modelling/Evaluation Services – Assessing the cost-effectiveness and budget impact of healthcare interventions.
- Patient-Reported Outcomes Analysis – Measuring quality of life, treatment satisfaction, and other patient-centered metrics.
- Market Access Solutions – Supporting pharmaceutical and medical device companies in obtaining favorable reimbursement terms.
- Real-World Data Analytics – Analyzing large datasets from healthcare providers, insurers, and registries to generate insights.
By Therapeutic Area:
- Oncology
- Cardiovascular diseases
- Neurology
- Rare diseases
- Immunology and infectious diseases
By End-User:
- Pharmaceutical and biotech companies
- Medical device manufacturers
- Healthcare providers and payers
- Government agencies and policy-makers
Regional Market Insights
North America
North America dominates the HEOR market, supported by advanced healthcare infrastructure, significant pharmaceutical R&D spending, and strong regulatory frameworks. The United States, in particular, leads in the adoption of value-based healthcare, creating sustained demand for HEOR services.
Europe
Europe is a significant player in the HEOR space due to the presence of established health technology assessment agencies such as the National Institute for Health and Care Excellence (NICE) in the UK. Strict cost-effectiveness evaluations are standard practice before approving new drugs, boosting demand for HEOR expertise.
Asia-Pacific
Asia-Pacific is expected to witness the fastest growth during the forecast period. Factors include increasing healthcare expenditure, expanding pharmaceutical manufacturing capabilities, and the gradual adoption of value-based care models in countries like China, Japan, and India.
Latin America and Middle East & Africa
Emerging economies are beginning to integrate HEOR methodologies into healthcare policy and reimbursement systems, though adoption is slower compared to developed regions. Nonetheless, growing awareness and international collaborations are expected to fuel market potential.
Challenges and Restraints
Despite its growth trajectory, the HEOR market faces several challenges:
- Data Privacy Regulations – Stringent data protection laws, such as GDPR in Europe, can limit access to patient-level data for HEOR analysis.
- High Service Costs – Comprehensive HEOR projects require significant investment in data collection, statistical modeling, and specialized expertise.
- Standardization Issues – Lack of uniform methodologies and reporting standards across regions can complicate cross-border research.
Future Opportunities
The next decade will bring several opportunities for the HEOR industry:
- Artificial Intelligence and Machine Learning Integration – AI-powered analytics can process vast datasets faster and more accurately, enhancing predictive modeling in HEOR.
- Personalized Medicine Research – HEOR can play a vital role in assessing the cost-effectiveness of precision therapies tailored to individual genetic profiles.
- Telehealth Impact Studies – As telemedicine becomes more prevalent, HEOR can evaluate its economic and clinical benefits in diverse patient populations.
- Global Collaboration Networks – Cross-border partnerships between HEOR firms, universities, and healthcare providers will expand the scope and quality of research.
